CD274 and neoplasm: Currently, biomarkers, including programmed death ligand 1 (PD-L1), the microsatellite instability (MSI) status, Epstein–Barr virus (EBV) infection and tumor mutational burden (TMB), are often applied clinically to predict immunotherapy efficacy (Figure 1).